Company Filing History:
10 out of 870 
1 out of 158 
1 out of 1 Years Active: 1987-2000
Title: Innovations by Marc Girard: Pioneering Research in Virology
Introduction
Marc Girard is a distinguished inventor based in Paris, France, known for his significant contributions to the field of virology. With a robust portfolio of 12 patents, Girard has played a vital role in advancing our understanding of viral infections, particularly those associated with human and simian immunodeficiency viruses.
Latest Patents
Marc Girard's latest patents demonstrate his focus on innovative compositions that enhance the immune response against retroviral infections. One notable patent is for a composition containing a B epitope of the envelope glycoprotein of a retrovirus, which may include epitopes from various other viruses, including the human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), and human T-cell lymphotropic viruses (HTLV-I and HTLV-II). Another significant patent details a method for inducing neutralizing antibodies against viral infections by administering a combination of virus envelope glycoproteins and oligopeptides derived from them. These innovations hold promise for developing effective vaccines against retroviruses capable of inducing AIDS.
Career Highlights
Marc Girard has had a profound impact on the field of virology through his work at prestigious institutions. He has notably collaborated with Institut Pasteur, a leading research center focused on infectious diseases, as well as Transgene S.A., a biotechnology company dedicated to developing immunotherapies for various diseases. His innovative research has not only expanded scientific knowledge but also paved the way for novel approaches in vaccine development.
Collaborations
Throughout his career, Marc Girard has collaborated with esteemed colleagues, including Sylvie van der Werf and Marie-Paule Kieny. These collaborations have facilitated groundbreaking research and have enhanced the effectiveness of immunological studies aimed at combating viral infections. The synergy of their expertise has contributed to advancements in vaccine science and public health.
Conclusion
Marc Girard's innovative spirit and dedication to virology continue to inspire future research endeavors. His extensive patent portfolio highlights his commitment to developing solutions that address critical public health challenges posed by viruses. As research institutions and companies build upon his findings, the potential for impactful medical advancements remains promising.